PDL BioPharma — Investor Presentation (October 2016)
41 slides from PDL BioPharma's investor presentation, Oct 18, 2016
Slide 1: Corporate Presentation
PDL Corporate Presentation October 18, 2016
Slide 2: Mission
PDL Mission
Slide 3: PDL Mission
PDL Mission PDL BioPharma seeks to optimize its return on investments so as to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries.
Slide 4: Overview
PDL Overview
Slide 5: PDL Today
Specialty Pharma Royalty & Debt Deals PDL Today Four debt deals representing deployed and committed capital of $268 and $308 million, respectively: Lensar, Direct Flow Medical, kaléo, and CareView. Seven royalty transactions representing deployed and committed capital of $496 and $537 million, respe
Slide 6: PDL Future
PDL PDL Future ¥ Acquiring additional specialty pharma products for Noden Pharma DAC. Specialty Pharma Y Significant focus. v Using proceeds from completed deals to fund new product acquisiti Royalty & Debt Deals Fewer royalty still fewer debt transactio Data from Eli Lilly’s Phase 3 trial in patien
Slide 7: Experienced Leadership
POL Experienced Leadership Management Board of Directors John McLaughlin Paul Edick President & CEO David Gryska OWE eecl Conesel & Jody Lindell Secretary John McLaughlin Peter Garcia Samuel Saks VP & Chief Financial Officer Paul Sandman Danny Hart Harold E. Selick, Ph.D. VP, Business Development Le
Slide 8: Noden Pharma
PDL NODEN y PHARMA
Slide 9: Hypertension
PDL Hypertension Q Chronic condition with serious long-term cardiovascular implications which affects about 29% of the US adult population = 78 million in US alone. Q Majority of hypertension diagnosis and management occurs in primary care setting (PCP) with rare referrals when there are severe co-m
Slide 10: Tekturna Products in Noden
PDL Tekturna Products in Noden a US = Tekturna® - aliskiren is a direct renin inhibitor for the treatment of hypertension that reduces plasma renin by inhibiting the conversion of angiotensinogen to angiotensin |. © Not for use with ACEs or ARBs in patients with diabetes or renal impairment, © Appro
Slide 11: Tekturna Products Labeling
PDL Tekturna Products Labeling For full prescribing information for Tekturna and Tekturna HCT, please visit: www.tekturna.com.
Slide 12: Tekturna: Efficacy Profile
PDL Tekturna: Efficacy Profile Q Randomized, double-blind, placebo controlled studies in patients. Q 2,730 patients administered doses of 75-600 mg of Tekturna and 1,213 patients on placebo. = Clinical effects seen at approved doses of 150 mg and 30 mg. study | Placebo Mean 150 mg 300 mg uf Change P
Slide 13: Tekturna: Safety Profile
PDL Tekturna: Safety Profile Q Safety data in more than 6,460 patients, including 1,740 treated for longer than 6 months and more than 1,250 treated for longer than 1 year. Q Discontinuation of therapy due to clinical adverse event occurred in 2.2% of Tekturna treated patients compared to 3.5% of pl
Slide 14: Tekturna: Safety Profile
PDL Placebo-Controlled Trials AdverseEvent —_Tekturna(%) Placebo (%) Edema 0.4 05 Diarrhea a4 1.2 Cough 1a. 0.6 Rash 1.0 0.3 Elevated Uric Acid 0.4 01 Gout 0.2 01 Renal Stones. 0.2 0.0 Tekturna: Safety Profile Selected AE’s in Patients with Type 2 Diabetes and Chronic Kidney Disease, CV Disease, or
Slide 15: Tekturna HCT: Efficacy
PDL Tekturna HCT: Efficacy ASTRIDE Study ATTAIN Study Study Design Aliskiren HCT comparedto _Alliskiren HCT vs. amlodipine in patients with _ramiprilin obese ACTION Study Aliskiren HCT in older patients with Stage 2 ACQUIRE Study Aliskiren alone vs. Aliskiren HCT Stage 2 systolic patients (BMI230 —_
Slide 16: Tekturna HCT: Efficacy
PDL Tekturna HCT: Efficacy Q Safety data in more than 2,700 patients. Q In placebo controlled trials, discontinuation of therapy due to clinical AE occurredin 2.7% of Tekturna HCT treated patients compared to 3.6% of placebo patients. Placebo-Controlled Trials Adverse Event Tekturna HCT (%) Placebo
Slide 17: SPRINT Trial
PDL SPRINT Trial Q Objective = Randomized, controlled, open label trial to determine whether reducing systolic blood pressure from <140 mm Hg to <120 mm Hg reduces CV disease (MI, other acute coronary syndromes, stroke, heart failure or death from CV causes). Q Patients = 9,361 randomized into two g
Slide 18: Potential Effect: SPRINT Trial
PDL Potential Effect: SPRINT Trial O Surveyed KOLs believe that SPRINT trial has created momentum to modify guidelines with respect to blood pressure goals. Q ~80% of physicians surveyed would lower treatment goals to ~120 mm Hg from standard target of 140 mm Hg. Q ACEs and ARBs use most likely to i
Slide 19: Tekturna: Market Research
PDL Tekturna: Market Research Q Novartis = No active sales or marketing efforts with respect to Tekturna products for last 3 years. Q Market Research = 21 in-depth qualitative interviews with PCPs, cardiologists, hypertension specialists, and payers. = 209 participated in quantitative survey of PCPs
Slide 20: Potential Future Increases
PDL Potential Future Increases Projected Change in Tekturna and Tekturna Use in Future — Survey Results PCP Tek Prescriber Sub-Analysis (n=120) Dincreased increased Biincreased Biincreased Dincreased Biincreased Cistayed Same Stayed same Cistayed Same Stayed same Cistayed Same Stayed same Decreased
Slide 21: Potential Future Increases
PDL Potential Future Increases Projected Change in Tekturna and Tekturna Use in Future — Survey Results All Tek Non-Prescriber Sub-Analysis (n=57) Before Reviewing Profile After Reviewing Profile increased increased increased H increased increased increased Stayed Same stayed Same stayed Same | Stay
Slide 22: Noden Pharma Entities
PDL Noden Pharma Entities OQ Noden DAC * Domiciled in Ireland. = Responsible for development and commercialization activities worldwide. = Responsible for bulk tablet manufacture worldwide and fill-and-finish ex-US. Q Noden US = Domiciled in Delaware. = Responsible for commercialization in US. = Res
Slide 23: Transition from Novartis
PDL Transition from Novartis Q Commercialization » US o Novartis distributing through September 30, 2016 and Noden receiving a transfer of profit. o Noden USA assumed commercialization responsibilities on October 1, 2016. = Ex-US o Novartis distributing until transfer of marketing authorizations (pr
Slide 24: Noden Team
PDL Noden Team OQ CEO = Elie Farah, previously CEO and President of Merus Labs and Transition Therapeutics, Director of M&A at Boehringer Ingelheim. QO Head of Sales and Marketing US = Michael McCann, previously head of US Cardiovascular at Sanofi Genzyme, VP of Global Strategic Marketing for Cardio
Slide 25: Novartis/Tekturna Deal
PDL Novartis/Tekturna Deal Q Total Potential Size = Up to $334 million. QO Closing Payments = $110 million to Novartis. = $40 million to Noden as working capital. O First Anniversary = $89 million due to Novartis. Q Milestones = Up to $95 million based on sales levels and generic competition. O Fina
Slide 26: Tekturna IP
PDL Tekturna IP Q Tekturna is protected by multiple patents covering composition of matter, pharmaceutical formulation and methods of manufacture. Q United States = Composition of matter protection to 2018 for Tekturna; listed in the Orange Book; possible extension for 6 months with successful compl
Slide 27: Royalty & Debt Investments
PDL Royalty & Debt Investments
Slide 28: Royalty & Debt Investments
PDL 16 Royalty & Debt Investments Rovalty Acquisition Rovalty Acquisition ky bella — ses.00n000 aman “iy 2016 september 2015 5 eared mae tages concluded = ceil O) caReMia Deals ARIAD ry $40,000,000 uptesisooncoo | seoconme s6s,c00.00 : RovaltyAcauistion | SeniorSecuredlow $15,500,000 “une 2018 Oo @
Slide 29: On-Going Transactions
PDL On-Going Transactions Technology Deal Summary KYBELLA® is an injectable approved for reduction of chinfatandcontains synthetic deoxycholicacid which destroys fat cells, resulting ina noticeable reduction infullnessunder the chin, = $8.5 millionfor anindividual'sroyaty. = $1million milestone upon
Slide 30: On-Going Transactions
PDL On-Going Transactions Entity Structure Technology Deal Summary Auvi-Q for delivery ofepinephrinetotreat = $150M innotes backed by 20% net salesof Auvi-Qand 10% of net sales k | severe allergicreactions, and EVZIOfor Of EVZIO by kalo. The Notes pay interest at 13%with an expected final alieo Debt
Slide 31: Concluded Transactions
PDL Entity Structure MERUS LABS Debt Concluded Transactions Technology Commercialization of Enablex,a treatment for overactive bladder, and Vancocin, anintravenousantibiotic. Deal Summary = $55M of Notes secured by assets of Merus. © In September 2013 Merus repaid PDL in full plus pre-payment fees,
Slide 32: Investment Track Record
PDL Investment Track Record Cash 4x Cash Cash Return Transaction Maturity Total © Amount Received Return (Money _Pre-Taxed Date Date Committed Invested _byPDL___(Years)__ Multiple) __IRR% Merus Labs Jul-2012 Sep-2013 $ 55.0 $ 54.6 $ 60.2 42 11 15.1% AxoGen* Oct-2012 Nov-2014 20.8 26.4 40.0 2.2 1s 24
Slide 33: Financials
PDL Financials
Slide 34: Second Quarter 2016
PDL Second Quarter 2016 Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2016 2015 2015 Royalties from Queen et al. patents $14,232 $ 116,884 $ 135,687 _$ 244,694 Royalty rights - change in fair value (855) 12,216 23,578 Interest revenue 7,343 8,966 19,5
Slide 35: Second Quarter 2016
PDL Second Quarter 2016 June 30, December 31, 2016 2015 Cash, cash equivalents and investments 190,854 220,352 Total notes receivable 372,182 364,905 Total royalty rights - at fair value 339,338 399,204 Total term loan payable 24,966 Convertible notes payable 232,847 228,862 $ $ $ $ $ $ Total assets
Slide 36: PDL Debt
PDL PDL Debt O Convertible Note = $246 million due in February 2018. = Current conversion price per share is $9.17 and increased by bond hedge to $10.36. Q Buy Backs = In November 2015, PDL bought back $53.6 million in aggregate principal for $43.7 million in cash in open market transactions. = Note
Slide 37: Solanezumab
PDL Solanezumab
Slide 38: Potential Royalty
PDL Potential Royalty Q Solanezumab = Humanized antibody targeting beta amyloid, which is believed to cause Alzheimer’s Disease, designed by PDL and being developed by Eli Lilly. Q Previous Phase 3 Trials = In 2012, Lilly reported that its initial Phase 3 trials in patients with mild and moderate Al
Slide 39: Potential Royalty
PDL Potential Royalty Q Current Phase 3 = Based on the results in its initial Phase 3 trials, Lilly commenced a new Phase 3 trial in patients with only mild Alzheimer’s Disease in 2013. = Study uses PET scans or similar screens to distinguish between patients with Alzheimer’s Disease and those with
Slide 40: Conclusion
PDL Conclusion
Slide 41: Investment Highlights
PDL Investment Highlights Q Tekturna and Tekturna HCT are important unique products for treatment of hypertension with potential upside in revenues if promoted appropriately. QO Noden is a tax efficient vehicle and additional spec pharma products will be added. QO 16 royalty and debt deals with 11 o